Corbus Pharmaceuticals Holdings Inc CRBP

Healthcare Biotechnology

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

NDAQ:CRBP - Post by User

Corbus Pharmaceuticals Holdings Inc

<< Previous

Bullboard Posts

Next >>

Post by satchmo6on Mar 04, 2021 6:46pm

165 Views

Post# 32724289

ANY AFFILIATION WITH -----BELOW

WAS LOOKING FOR ORBUS PHARMA ca2010 --nowtrying to suck more blood money out of previous losers from 50 cents down to 13 cenrs 2011---a failed --p n d---but not for them---it wasaATM MACHINE-------------------AAAAAAARRRRRRRRRGGGGGGGGGGGGGGHHHHHH